Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

Importance In the United States, the lifetime risk of being diagnosed with prostate cancer is
approximately 11%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age …

Background The comparative effectiveness of treatments for prostate cancer that is detected
by prostate-specific antigen (PSA) testing remains uncertain. Methods We compared active …

Context In men with prostate cancer (PCa) treated with curative intent, controversy exists
regarding the impact of biochemical recurrence (BCR) on oncological outcomes. Objective …

Importance Prostate cancer is the most common cancer diagnosis made in men with more
than 160 000 new cases each year in the United States. Although it often has an indolent …

Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …

Background Robust data on patient-reported outcome measures comparing treatments for
clinically localized prostate cancer are lacking. We investigated the effects of active …

Background Inherited mutations in DNA-repair genes such as BRCA2 are associated with
increased risks of lethal prostate cancer. Although the prevalence of germline mutations in …